Tags

Type your tag names separated by a space and hit enter

Cannabinoids.

Abstract

Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of G-protein coupled cannabinoid receptors, CB(1) and CB(1), have been cloned and several putative endogenous ligands (endocannabinoids) have been detected during the past 15 years. The main endocannabinoids are arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG), derivatives of arachidonic acid, that are produced "on demand" by cleavage of membrane lipid precursors. Besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the CB receptors and inhibitors of endocannabinoid degradation. Cannabinoid receptors are distributed in the central nervous system and many peripheral tissues, including immune system, reproductive and gastrointestinal tracts, sympathetic ganglia, endocrine glands, arteries, lung and heart. There is evidence for some non-receptor dependent mechanisms of cannabinoids and for endocannabinoid effects mediated by vanilloid receptors. Properties of CB receptor agonists that are of therapeutic interest include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and antineoplastic effects. The current main focus of clinical research is their efficacy in chronic pain and neurological disorders. CB receptor antagonists are under investigation for medical use in obesity and nicotine addiction. Additional potential was proposed for the treatment of alcohol and heroine dependency, schizophrenia, conditions with lowered blood pressure, Parkinson's disease and memory impairment in Alzheimer's disease.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    Nova-Institut, Goldenbergstrasse 2, D-50354 Hürth, Germany. franjo.grotenhermen@nova-institut.de

    Source

    MeSH

    Animals
    Anxiety Disorders
    Cannabidiol
    Cannabinoid Receptor Modulators
    Cannabinoids
    Dronabinol
    Drug Evaluation
    Drug Evaluation, Preclinical
    Humans
    Psychotropic Drugs
    Receptors, Cannabinoid

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    16266285

    Citation

    Grotenhermen, Franjo. "Cannabinoids." Current Drug Targets. CNS and Neurological Disorders, vol. 4, no. 5, 2005, pp. 507-30.
    Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4(5):507-30.
    Grotenhermen, F. (2005). Cannabinoids. Current Drug Targets. CNS and Neurological Disorders, 4(5), pp. 507-30.
    Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005;4(5):507-30. PubMed PMID: 16266285.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cannabinoids. A1 - Grotenhermen,Franjo, PY - 2005/11/4/pubmed PY - 2006/1/24/medline PY - 2005/11/4/entrez SP - 507 EP - 30 JF - Current drug targets. CNS and neurological disorders JO - Curr Drug Targets CNS Neurol Disord VL - 4 IS - 5 N2 - Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of G-protein coupled cannabinoid receptors, CB(1) and CB(1), have been cloned and several putative endogenous ligands (endocannabinoids) have been detected during the past 15 years. The main endocannabinoids are arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG), derivatives of arachidonic acid, that are produced "on demand" by cleavage of membrane lipid precursors. Besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the CB receptors and inhibitors of endocannabinoid degradation. Cannabinoid receptors are distributed in the central nervous system and many peripheral tissues, including immune system, reproductive and gastrointestinal tracts, sympathetic ganglia, endocrine glands, arteries, lung and heart. There is evidence for some non-receptor dependent mechanisms of cannabinoids and for endocannabinoid effects mediated by vanilloid receptors. Properties of CB receptor agonists that are of therapeutic interest include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and antineoplastic effects. The current main focus of clinical research is their efficacy in chronic pain and neurological disorders. CB receptor antagonists are under investigation for medical use in obesity and nicotine addiction. Additional potential was proposed for the treatment of alcohol and heroine dependency, schizophrenia, conditions with lowered blood pressure, Parkinson's disease and memory impairment in Alzheimer's disease. SN - 1568-007X UR - https://www.unboundmedicine.com/medline/citation/16266285/Cannabinoids_ L2 - http://www.eurekaselect.com/90804/article DB - PRIME DP - Unbound Medicine ER -